|
Match
|
Document |
Document Title |
|
|
US20120322766 |
USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS
The present invention relates to the use of compounds, in which the pharmacophores of quinolone and oxazolidinone are chemically linked together through a linker that is stable under physiological... |
|
|
US20120135961 |
USE OF OXAZOLIDINONE-QUINOLINE HYBRID ANTIBIOTICS FOR THE TREATMENT OF ANTHRAX AND OTHER INFECTIONS
The present invention relates to the use of compounds, in which the pharmacophores of quinolone and oxazolidinone are chemically linked together through a linker that is stable under physiological... |
|
|
US20150065488 |
METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN POLYMERIZATION
The present invention relates to methods of treatment of clinical disorders associated with protein polymerization comprising administering, to a subject, an effective amount of carbamazepine,... |
|
|
US20120129839 |
METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN POLYMERIZATION
The present invention relates to methods of treatment of clinical disorders associated with protein polymerization comprising administering, to a subject, an effective amount of carbamazepine,... |
|
|
US20150099740 |
TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention... |
|
|
US20130059829 |
TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention... |
|
|
US20130225540 |
SUPPRESSION OF GLIAL FIBRILLARY ACIDIC PROTEIN
Provided herein are methods of decreasing glial fibrillary acidic protein (GFAP) levels in a cell. Such methods include administering an effective amount of a GFAP lowering compound to the cell.... |
|
|
US20140322311 |
CRUSH RESISTAN DELAYED-RELEASE DOSAGE FORM
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one... |
|
|
US20140079780 |
Crush resistant delayed-release dosage forms
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one... |
|
|
US20110150775 |
GENOMIC APPROACHES TO FETAL TREATMENT AND DIAGNOSIS
The present invention provides systems for developing and/or testing therapies for prenatal diseases and conditions including Down Syndrome. The present invention also provides diagnostic methods... |
|
|
US20140073632 |
TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS
Novel CFTR corrector compounds that are effective in rescuing halide efflux in a cell are provided. Also provided are methods for treating protein folding disorders (e.g., cystic fibrosis). The... |
|
|
US20120264703 |
Methods And Compositions For The Treatment Of Anxiety Disorders, Including Post Traumatic Stress Disorder (PTSD) And Related Central Nervous System (CNS) Disorders.
The present invention provides novel methods and formulations for treating anxiety disorders, including Post Traumatic Stress Disorder, in human subjects employing coordinate treatment using α and... |
|
|
US20130289020 |
CXCR4 Receptor Antagonists
Disclosed are compounds that are antagonists of the CXCR4 receptor. |
|
|
US20130224289 |
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. |
|
|
US20120282307 |
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. |
|
|
US20120064129 |
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. |
|
|
US20140343044 |
METHOD FOR THE TREATMENT OF DRAVET SYNDROME
A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its... |
|
|
US20110015134 |
Method of treatment for early stage cancer
This patent describes a method and materials to treat cancer diagnosed at an early stage, particularly breast cancer. It considers that metastatic breast cancer growth includes periods of... |
|
|
US20130142882 |
METHODS AND COMPOSITIONS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF BONE CANCER PAIN
The present invention provides methods and compositions for treating, preventing, modifying (reducing), or managing bone cancer pain by cyclohexenone compounds. |
|
|
US20110086818 |
METHODS, COMPOSITIONS, AND KITS FOR TREATING PAIN AND PRURITUS
The invention features methods, compositions, and kits for selective inhibition of pain-and itch sensing neurons (nociceptors and pruriceptors) by drug molecules of small molecule weight, while... |
|
|
US20140093592 |
ESKETAMINE FOR THE TREATMENT OF TREATMENT-REFRACTORY OR TREATMENT-RESISTANT DEPRESSION
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a... |
|
|
US20130236573 |
ESKETAMINE FOR THE TREATMENT OF TREATMENT-REFRACTORY OR TREATMENT-RESISTANT DEPRESSION
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a... |
|
|
US20110150766 |
Transdermal patch with fatal overdose protection
A transdermal patch having a top region containing an antagonist followed by a bottom region containing an agonist, whereby the bottommost end of the bottom region is secured to the skin of the... |
|
|
US20150025063 |
Antiparkinsonian Action of Phenylisopropylamines
A method of treating a subject for Parkinson's disease comprises administering said subject a phenylisopropylamine in an amount effective to treat said Parkinson's disease. In some embodiments the... |
|
|
US20110123618 |
Controlled release formulation of lamotrigine
Rapidly disintegrating multiparticulate controlled release formulations of lamotrigine having an improved pharmacokinetic profile and improved patient compliance, and process of preparing the... |
|
|
US20120232062 |
AZAINDAZOLES TO TREAT FLAVIVIRIDAE VIRUS INFECTION
Azaindazole compounds are useful for treating Flaviviridae virus infection, including HCV infection. |
|
|
US20110268820 |
USE OF SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR JOINT FUSION AND OTHER REPAIR OR HEALING OF CONNECTIVE TISSUE
Methods for facilitating joint immobilization or fusion using selective estrogen receptor modulator (SERM) such as raloxifene are disclosed. The SERM may be administered systemically or locally.... |
|
|
US20120128735 |
METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form. |
|
|
US20120064168 |
METHODS OF TREATMENT USING A GASTRIC RETAINED GABEPENTIN DOSAGE
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form. |
|
|
US20110009351 |
SCREENING ASSAY TO IDENTIFY CORRECTORS OF PROTEIN TRAFFICKING DEFECTS
The present invention relates to a novel assay or screen for identifying compounds with potential therapeutic value for the treatment of protein trafficking diseases such as Cystic Fibrosis (CF)... |
|
|
US20130040939 |
Oral Suspension Formulations of Esclicarbazepine Acetate
An oral suspension formulation comprising eslicarbazepine acetate and a pharmaceutically acceptable liquid vehicle. |
|
|
US20150087630 |
METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER
Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R3, R5 and R6 are as defined herein. |
|
|
US20130261104 |
METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER
Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R3, R5 and R6 are as defined herein. |
|
|
US20140234443 |
5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF
Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and... |
|
|
US20120219641 |
5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF
Novel 5-HT3 receptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and... |
|
|
US20130202657 |
FOAMS OR PARTICLES FOR APPLICATIONS SUCH AS DRUG DELIVERY
The present invention generally relates to foams and, in particular, to foams for applications such as drug delivery, and particles that are made from such foams. One aspect relates to foams or... |
|
|
US20140213579 |
METHOD OF WEIGHT MANAGEMENT
Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or... |
|
|
US20110230469 |
Method to Determine the Risk for Side Effects of an SSRI Treatment in a Person
A new method is found to determine an increased risk for side effects of an SSRI treatment in a person by genotyping the person for the presence of the 102 C/C DNA sequence in the 5-HT2A receptor... |
|
|
US20130035304 |
SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS
This invention relates to compounds which selectively bind to the survival protein MCL-1 with high affinity and selectivity, pharmaceutical compositions containing such compounds and the use of... |
|
|
US20110071102 |
Compositions and Methods to Treat Recurrent Medical Conditions
The invention describes methods and compositions for alleviating recurrent medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is... |
|
|
US20150209327 |
METHODS FOR THE TREATMENT OF OBESITY USING APREMILAST
Methods of treating, managing or preventing obesity and overweight are disclosed. Specific methods encompass the administration of apremilast, alone or in combination with additional active agents... |
|
|
US20150157558 |
METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form. |
|
|
US20140023615 |
THERMO-SENSITIVE, MUCOADHESIVE OR DERMOADHESIVE, AND PENETRATION-ENHANCING FORMULATIONS FOR TOPICAL DELIVERY OF THERAPEUTICS
The present invention provides thermo-sensitive, mucoadhesive biopolymer formulations that enhance the penetration of therapeutics across the skin or mucosal surfaces. In a preferred embodiment,... |
|
|
US20140378401 |
Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly... |
|
|
US20120071464 |
METHOD OF TREATMENT OF OBSESSIVE COMPULSIVE DISORDER WITH ONDANSETRON
Methods for treating obsessive compulsive disorder are described. In one method, a serotonin reuptake inhibitor (SRI) and ondansetron or a pharmaceutically acceptable salt thereof is administered... |
|
|
US20110294763 |
TRANSDERMAL DELIVERY OF DICOLFENAC, CARBAMAZEPINE AND BENZYDAMINE
The invention discloses solutions of diclofenac, carbamazepine and benzydamine, at therapeutically desirable concentrations and the solutions stable for extended periods of time at room temperature. |
|
|
US20110206780 |
MORPHINAN MODULATORS OF NMDA RECEPTORS, SIGMA1 RECEPTORS, SIGMA2 RECEPTORS, AND/OR A3B4 NICOTINIC RECEPTORS
The present invention relates to new morphinan modulators of NMDA receptors, σ1 receptors, σ2 receptors, and/or α3β4 nicotinic receptors, pharmaceutical compositions thereof, and methods of use... |
|
|
US20050049240 |
Tetrahydroisochinolines, their production and the use thereof as analgesics
The invention relates to novel tetrahydroisoquinolines, to processes for their preparation and to their use for producing pharmaceuticals for the treatment and/or prophylaxis of diseases, in... |
|
|
US20150080296 |
Nutritive Fragments, Proteins and Methods
Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a protein digestibility corrected amino acid score (PDCAAS) that exceeds a benchmark protein. Also provided are... |
|
|
US20120309742 |
USE OF METABOTROPIC GLUTAMATE RECEPTORS
The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction. |